An impressive variety of new methodologies for the preparation of 18 F-labelled tracers and
ligands has appeared over the last decade. Most strategies of the newly developed …

New platforms are enabling radiochemistry to be carried out in tiny, microliter-scale volumes,
and this capability has enormous benefits for the production of radiopharmaceuticals. These …

Fluoride is one of the key chemical elements in human life and chemical industry, which also
shows the high toxicity. A fluorescent probe (ZYP-1) based 1, 8-naphthalimide has been …

Aliphatic nucleophilic substitution (SN2) with [18F] fluoride is the most widely applied
method to prepare 18F-labeled positron emission tomography (PET) tracers. Strong basic …

Single domain antibody fragments (sdAbs) labeled with 18F have shown promise for
assessing the status of oncological targets such as the human epidermal growth factor …

Antibody-based dual-modality (PET/fluorescence) imaging enables both presurgery antigen-
specific immuno-PET for noninvasive whole-body evaluation and intraoperative …

Type I interferons (IFNs) are critical effectors of emerging cancer immunotherapies designed
to activate pattern recognition receptors (PRRs). A challenge in the clinical translation of …

The growing discovery and development of novel radiopharmaceuticals and radiolabeling
methods requires an increasing capacity for radiochemistry experiments. However, such …

Abstract The 2-[18 F] fluoro-2-deoxy-d-glucose ([18 F] FDG) is the most well-known
radiopharmaceutical positron emitter, in both clinical and preclinical fields. Based on a …

ImmunoPET agents are being investigated to assess the status of epidermal growth factor
receptor 2 (HER2) in breast cancer patients with the goal of selecting those likely to benefit …